Errant Gene Therapeutics, LLC et al v. Sloan-Kettering Institute for Cancer Research

  1. January 02, 2018

    Sloan Kettering Gets Trimmed Fees In IP Fight

    A New York federal judge ordered Errant Gene Therapeutics LLC to pay the Sloan Kettering Institute for Cancer Research $88,339 in attorneys' fees Tuesday after the biopharmaceutical company was sanctioned for using protected information from a gene therapy patent rights case in other suits.

  2. June 06, 2017

    Sloan Kettering Secures Sanctions In Drug IP Case

    A New York magistrate judge sanctioned a biopharmaceutical company and its counsel Monday for using protected information from its now-dismissed lawsuit against the Sloan Kettering Institute for Cancer Research over gene therapy patent rights to file suits in other courts, saying this behavior clearly violated a court order.

  3. February 09, 2017

    Sloan Kettering Seeks More Sanctions In Drug IP Case

    The Sloan Kettering Institute again asked a New York federal judge to sanction a biopharmaceutical company and its counsel in a now-dismissed lawsuit over gene therapy patent rights, saying Wednesday the company used protected documents from this case in a newly filed state court matter concerning the same issues.

  4. January 20, 2017

    Sanction Bid in Dismissed IP Case Still Valid, Sloan Says

    A lawyer representing the Sloan Kettering Institute on Friday urged a New York federal judge to keep alive a sanction bid against counsel for a gene therapy company that sued the cancer researcher, despite the recent dismissal of the underlying lawsuit.

  5. January 18, 2017

    Niro Attys Again Face Sanctions In Sloan-Kettering IP Row

    A New York federal judge ruled Wednesday that a biopharmaceutical company can refile its suit seeking to reclaim gene therapy patent rights from the Sloan-Kettering Institute in state court, but said the company and its counsel must explain their delay in making the move or face sanctions.

  6. November 04, 2016

    Sloan-Kettering Says Niro Attys Filched Gene Therapy Docs

    The Sloan-Kettering Institute for Cancer Research has called for sanctions against an independent biopharmaceutical company trying to get back certain rights to a type of gene therapy for a blood disease and its counsel, arguing there have been multiple “willful” violations of a strict protective order.